<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819739</url>
  </required_header>
  <id_info>
    <org_study_id>PI2014_843_0006</org_study_id>
    <secondary_id>2014-001403-44</secondary_id>
    <nct_id>NCT02819739</nct_id>
  </id_info>
  <brief_title>Impact of Hyperoxia During Cardiopulmonary</brief_title>
  <acronym>CARDIOX</acronym>
  <official_title>Impact of Hyperoxia During Cardiopulmonary Bypass in the Occurrence of Cardiovascular Complications After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis implies that this work is the use of hyperoxia during cardiopulmonary bypass
      by his heart preconditioning effect is associated with a lower incidence of cardiac
      arrhythmias (atrial fibrillation, tachycardia or ventricular fibrillation) and lesions of
      myocardial ischemia-reperfusion injury in cardiac surgery postoperative.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2014</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurred within 15 days after surgery, disorders of heart rhythm (atrial fibrillation, tachycardia or ventricular fibrillation)</measure>
    <time_frame>15 days after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Cardiac Complications</condition>
  <arm_group>
    <arm_group_label>normoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperoxia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medical oxygen</intervention_name>
    <arm_group_label>hyperoxia</arm_group_label>
    <arm_group_label>normoxia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patient â‰¥ 18 years

          -  Patient operated cardiac surgery for myocardial revascularization (CABG) or surgical
             correction of valvular or combined surgery (CABG and valve disease) or ascending
             aortic surgery

          -  Signed Consent

          -  Affiliation to social security

        Exclusion Criteria:

          -  Permanent atrial fibrillation

          -  Cordarone therapy,

          -  Pregnant woman

          -  Patient under guardianship or trusteeship or private public law

          -  Internal pacemaker

          -  Hypothermia,

          -  Patient refusal,

          -  Cardiac surgery without extracorporal circulation (ECC),

          -  Participation in another study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama ABOU ARAB, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens-Picardie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

